FDF Japan

CPhI Japan | FDF | Japan’s Pharma Market Awaits You

Caution: Exhibitors. CPhI 365 Digital Solutions.

This is part of Informa Markets Division at Informa PLC.

Informa PLC owns this site and all copyright is theirs. Informa PLC is located at 5 Howick Place in London SW1P 1WG. Registered in England and Wales. Number 8860726.

FDF unites many elements of the finished dosage supply chain in one place, including Big Pharma, in/out-licensing specialists and end product distributors.

Japan's pharma market is expected to grow strongly in 2019. The growth of solid dosage formulations will increase by more than 10%. Generic drug classes are highlighted as having strong growth prospects. Japan's growing population and government initiatives to lower health expenditures are expected to lead to a higher volume share of generic drugs, at least 80% by 2020. The government of Japan is putting a lot of emphasis on the generic drug sector. They have even declared that the country's growth in generic drugs is \"imperative for Japan's long-term economic well-being.\".

Japan's exceptional reputation for quality in domestic manufacturing is not fading. In the CPhI Annual Report pharma Index*, Japan (7.95), alongside the USA (8.01) and Germany (8.07) were the top two countries for finished dose manufacturing.

CPhI Japan helps us to establish more connections in the industry. This will allow us to expand our business opportunities going forward.

Murthy S.N. Mokkarala, Associate Vice President, Hetero Labs Ltd.